The prognostic value of expression of HIF1α, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy

Table 5 Bio-chemical Progression-free survival in patients treated with exclusive RT and combined RT and ADT as a function of HIF1α, EGFR and VEGF-A expression

IHC expression	No ADT	ADT	p
	8-year bPFS (%)[95%CI]	8-year bPFS (%)[95%CI]
Low-HIF1α †	63.6 [40.7 – 99.5]	70.0 [46.7 – 100.0]	0.46
High-HIF1α ‡	68.0 [52.5 – 88.2]	80.7 [69.4 – 91.9]	0.30
No EGFR	82.2 [67.8 – 99.7]	100.0 [NA]	0.36
Weak EGFR **	37.3 [13.8 – 100.0]	74.1 [58.1 – 94.6]	0.15
Strong EGFR *	62.5 [38.9 – 100.0]	61.5 [40.0 – 94.6]	0.65
low VEGF-A ¶	68.6 [44.5 – 100.0]	74.8 [56.1 – 99.7]	0.33
high VEGF-A ¶	67.8 [45.9 – 84.2]	80.2 [68.0 – 94.7]	0.45

RT radiation therapy; IHC Immuno-histochemistry expression; ADT Androgen deprivation therapy.
† ≤ 50% nuclear.
‡ > 50% nuclear.
* > 50% with moderate intensity or >30% of cells with strong intensity.
**Not reaching the above criteria.
low VEGF-A = IRS score < 5, high VEGF-A = IRS score >5.

ISSN: 1748-717X